Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028” Report Highlights:
The gamma delta T cell therapy represents one of the most promising T cell therapies in clinical development which can be suggested by the rapid research and development activities among the pharmaceutical companies. The major companies in the market are presenting promising preclinical and clinical data of gamma delta T cell therapies. For instance in 2022, In8bio provided an update on ongoing phase-I clinical trial of INB-200. The novel gamma delta T cell product has shown manageable safety profile and promising progression free survival and overall survival rate. The encouraging data from clinical trial suggests the promising future of gamma delta T cell therapy in the management of cancer.
Apart from cancer, researchers are also expanding the role of gamma delta T cell therapy in the management of other diseases such as HIV, COVID-19, and other viral infections. Recently, Enochian Biosciences announced that US FDA has accepted a pre-investigational new drug request for a cell therapy treatment which combines autologous natural killer and gamma delta T-cells. Furthermore, several preclinical studies also indicate an innate involvement of gamma delta T cells in viral infections. The coming years will witness translation of these investigations in clinical trials, which will further propel the growth of market.
The rising investment form the pharmaceutical giants have led to the development of strong clinical pipeline of gamma delta T cell therapy products. The key players operating in the market are Acopedia, Takeda Pharma, Lava Therapeutics, TC Biopharma, Cytomed Therapeutics, Gamma delta Therapeutics and Adapate Therapeutics. The major drugs in the clinical pipeline include INB-200, LAVA-051, ADI-001, TCB-007, ACE-1813, KB-PD1, and several others. Apart from this, several pharmaceutical giants have also entered into collaboration, mergers, or other alliances to maintain their position in the market. In January 2022, Takeda Pharmaceutical announced the exercise of its option to acquire Adapate Therapeutics. Through this acquisition, Takeda will obtain Adapate antibody based gamma delta T-cell engager platform including pre-clinical candidate and discovery pipeline programs.
US is currently dominating the global initiatives in development of gamma delta T cell therapy driven by large number of ongoing clinical trials, presence of key players in the region, and increasing initiatives from various stake holders in the industry . Apart from this, US FDA is also granting orphan drug designation to gamma T cell therapies which provides several financial and non-financial incentives to boost the drug development process. For instance in 2021, US FDA has granted orphan drug designation to two gamma delta T cell therapies including GDX012 for acute myeloid leukemia and LAVA-051 for chronic lymphocytic leukemia.
As per our report findings, the global gamma delta T-cell therapy market is expected to surpass US$ 4 Million by 2028. The rise in cancer rates and the subsequent unavailability of effectively curing drugs will propel the growth of the market for coming years. In addition, new product launches, continuous investment by pharmaceutical companies, and increasing government initiatives will also contribute in growth of market. The report provides comprehensive analysis on the ongoing clinical trials in gamma delta T cell therapy. By analyzing the market dynamics, the future market opportunity of gamma delta T cell therapy in various cancers is also forecasted.
“Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028” Report Highlights:
- Commercialization Market Potential After Market Launch: > USD 4 Billion
- Insight on Key Drugs In Research & Development
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
- Adopted Approaches for Gamma Delta T Cell Therapy
The gamma delta T cell therapy represents one of the most promising T cell therapies in clinical development which can be suggested by the rapid research and development activities among the pharmaceutical companies. The major companies in the market are presenting promising preclinical and clinical data of gamma delta T cell therapies. For instance in 2022, In8bio provided an update on ongoing phase-I clinical trial of INB-200. The novel gamma delta T cell product has shown manageable safety profile and promising progression free survival and overall survival rate. The encouraging data from clinical trial suggests the promising future of gamma delta T cell therapy in the management of cancer.
Apart from cancer, researchers are also expanding the role of gamma delta T cell therapy in the management of other diseases such as HIV, COVID-19, and other viral infections. Recently, Enochian Biosciences announced that US FDA has accepted a pre-investigational new drug request for a cell therapy treatment which combines autologous natural killer and gamma delta T-cells. Furthermore, several preclinical studies also indicate an innate involvement of gamma delta T cells in viral infections. The coming years will witness translation of these investigations in clinical trials, which will further propel the growth of market.
The rising investment form the pharmaceutical giants have led to the development of strong clinical pipeline of gamma delta T cell therapy products. The key players operating in the market are Acopedia, Takeda Pharma, Lava Therapeutics, TC Biopharma, Cytomed Therapeutics, Gamma delta Therapeutics and Adapate Therapeutics. The major drugs in the clinical pipeline include INB-200, LAVA-051, ADI-001, TCB-007, ACE-1813, KB-PD1, and several others. Apart from this, several pharmaceutical giants have also entered into collaboration, mergers, or other alliances to maintain their position in the market. In January 2022, Takeda Pharmaceutical announced the exercise of its option to acquire Adapate Therapeutics. Through this acquisition, Takeda will obtain Adapate antibody based gamma delta T-cell engager platform including pre-clinical candidate and discovery pipeline programs.
US is currently dominating the global initiatives in development of gamma delta T cell therapy driven by large number of ongoing clinical trials, presence of key players in the region, and increasing initiatives from various stake holders in the industry . Apart from this, US FDA is also granting orphan drug designation to gamma T cell therapies which provides several financial and non-financial incentives to boost the drug development process. For instance in 2021, US FDA has granted orphan drug designation to two gamma delta T cell therapies including GDX012 for acute myeloid leukemia and LAVA-051 for chronic lymphocytic leukemia.
As per our report findings, the global gamma delta T-cell therapy market is expected to surpass US$ 4 Million by 2028. The rise in cancer rates and the subsequent unavailability of effectively curing drugs will propel the growth of the market for coming years. In addition, new product launches, continuous investment by pharmaceutical companies, and increasing government initiatives will also contribute in growth of market. The report provides comprehensive analysis on the ongoing clinical trials in gamma delta T cell therapy. By analyzing the market dynamics, the future market opportunity of gamma delta T cell therapy in various cancers is also forecasted.
1. INTRODUCTION TO GAMMA DELTA T CELL THERAPY
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview to Gamma Delta T Cell Therapy
2. GAMMA DELTA T CELL THERAPY VS. CONVENTIONAL THERAPIES
2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
2.5 Gamma Delta T Cell Therapy Vs. Others
3. ROLE OF GAMMA DELTA T CELLS IN CANCER
3.1 Gamma Delta T Cells in Cancer Progression
3.2 Anti Tumor Activity of Gamma Delta T Cells
4. ADOPTED APPROACHES FOR GAMMA DELTA T CELL THERAPY
4.1 Gamma Delta T Cell as Bispecific Antibodies
4.2 CAR Gamma Delta T Cells
5. GAMMA DELTA T CELL THERAPY: KEY DRUGS IN RESEARCH & DEVELOPMENT
6. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL PIPELINE OVERVIEW
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Phase
7. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & CLINICAL PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
8. GAMMA DELTA T CELL THERAPY IN LEUKEMIA
8.1 Role of Gamma Delta T Cells in Leukemia
8.2 Ongoing Clinical Research in Acute Leukemia
8.3 Clinical Trials in Chronic Lymphocytic Leukemia
8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia
9. GAMMA DELTA T CELL THERAPY IN LUNG CANCER
9.1 Overview
9.2 Ongoing Research & Development
9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer
10. GAMMA DELTA T CELLS IN BREAST CANCER
10.1 Overview
10.2 Ongoing Research & Development in Breast Cancer
10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer
11. GAMMA DELTA T CELLS IN COLORECTAL CANCER
11.1 Function of Gamma Delta T Cells in Colorectal Cancer
11.2 Ongoing Clinical Trials in Colorectal Cancer
11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
12. GAMMA DELTA T CELLS IN PANCREATIC CANCER
12.1 Overview
12.2 Ongoing Research & Development in Pancreatic Cancer
12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer
13. CURRENT CLINICAL RESEARCH IN OTHER CANCERS
13.1 Ongoing Clinical Trials in Neuroblastoma
13.2 Ongoing Clinical Trials in Glioblastoma
13.3 Ongoing Research & Development in Head & Neck Cancer
14. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW
14.1 Current Market Scenario
14.2 Market Potential of Gamma Delta T Cell Therapy Market
15. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS
15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
15.2 Gamma Delta T Cell Therapy Market: Challenges
16. GAMMA DELTA T CELL THERAPY FUTURE PROSPECTS
17. COMPETITIVE LANDSCAPE
17.1 Acepodia
17.2 Adaptate Therapeutics
17.3 Adicet
17.4 Cytomed Therapeutics
17.5 Gadeta
17.6 GammaDelta Therapeutics
17.7 IN8bio
17.8 Kiromic Biopharma
17.9 Lava Therapeutics
17.10 Takeda Pharmaceuticals
17.11 TC Biopharm
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview to Gamma Delta T Cell Therapy
2. GAMMA DELTA T CELL THERAPY VS. CONVENTIONAL THERAPIES
2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
2.5 Gamma Delta T Cell Therapy Vs. Others
3. ROLE OF GAMMA DELTA T CELLS IN CANCER
3.1 Gamma Delta T Cells in Cancer Progression
3.2 Anti Tumor Activity of Gamma Delta T Cells
4. ADOPTED APPROACHES FOR GAMMA DELTA T CELL THERAPY
4.1 Gamma Delta T Cell as Bispecific Antibodies
4.2 CAR Gamma Delta T Cells
5. GAMMA DELTA T CELL THERAPY: KEY DRUGS IN RESEARCH & DEVELOPMENT
6. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL PIPELINE OVERVIEW
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Phase
7. GLOBAL GAMMA DELTA T CELL CANCER THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & CLINICAL PHASE
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
8. GAMMA DELTA T CELL THERAPY IN LEUKEMIA
8.1 Role of Gamma Delta T Cells in Leukemia
8.2 Ongoing Clinical Research in Acute Leukemia
8.3 Clinical Trials in Chronic Lymphocytic Leukemia
8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia
9. GAMMA DELTA T CELL THERAPY IN LUNG CANCER
9.1 Overview
9.2 Ongoing Research & Development
9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer
10. GAMMA DELTA T CELLS IN BREAST CANCER
10.1 Overview
10.2 Ongoing Research & Development in Breast Cancer
10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer
11. GAMMA DELTA T CELLS IN COLORECTAL CANCER
11.1 Function of Gamma Delta T Cells in Colorectal Cancer
11.2 Ongoing Clinical Trials in Colorectal Cancer
11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
12. GAMMA DELTA T CELLS IN PANCREATIC CANCER
12.1 Overview
12.2 Ongoing Research & Development in Pancreatic Cancer
12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer
13. CURRENT CLINICAL RESEARCH IN OTHER CANCERS
13.1 Ongoing Clinical Trials in Neuroblastoma
13.2 Ongoing Clinical Trials in Glioblastoma
13.3 Ongoing Research & Development in Head & Neck Cancer
14. GAMMA DELTA T CELL THERAPY MARKET OVERVIEW
14.1 Current Market Scenario
14.2 Market Potential of Gamma Delta T Cell Therapy Market
15. GAMMA DELTA T CELL THERAPY MARKET DYNAMICS
15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
15.2 Gamma Delta T Cell Therapy Market: Challenges
16. GAMMA DELTA T CELL THERAPY FUTURE PROSPECTS
17. COMPETITIVE LANDSCAPE
17.1 Acepodia
17.2 Adaptate Therapeutics
17.3 Adicet
17.4 Cytomed Therapeutics
17.5 Gadeta
17.6 GammaDelta Therapeutics
17.7 IN8bio
17.8 Kiromic Biopharma
17.9 Lava Therapeutics
17.10 Takeda Pharmaceuticals
17.11 TC Biopharm
LIST OF FIGURES
Figure 1-1: History of T cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 2-1: Limitation of CAR T Cell Therapy
Figure 2-2: Limitations of TIL
Figure 2-3: Limitations of Monoclonal Antibodies
Figure 2-4: Drawback of Chemotherapeutic Drugs
Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 4-1: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
Figure 4-2: Functional Advantages of ?? T Cells for CAR T Cancer Therapy
Figure 4-3: CAR ?? T Cells – Mechanism of Action
Figure 5-1: ADI-001 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-2: LAVA-051 – Initiation & Completion Year of Phase-I/II Clinical Trial
Figure 5-3: DRI Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-4: Adoptive Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-5: GDX012 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-6: GDT002 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 6-1: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Company, 2022 till 2028
Figure 6-2: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Country, 2022 till 2028
Figure 6-3: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Indication, 2022 till 2028
Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase, 2022 till 2028
Figure 8-1: Global – Leukemia Incidences & Mortality (Million), 2020 & 2040
Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
Figure 8-3: Mechanism of Action of V?9/CD123 Bispecific Antibody
Figure 8-4: Global – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-5: US – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-6: Europe – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-7: China – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-8: Japan – Estimated Leukemia Cancer Cases, 2021-2028
Figure 9-1: Global – Lung Cancer Incidences & Mortality (Million), 2020 & 2040
Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer
Figure 9-3: Global – Estimated Lung Cancer Cases, 2021-2028
Figure 9-4: US – Estimated Lung Cancer Cases, 2021-2028
Figure 9-5: Europe – Estimated Lung Cancer Cases, 2021-2028
Figure 9-6: China – Estimated Lung Cancer Cases, 2021-2028
Figure 9-7: Japan – Estimated Lung Cancer Cases, 2021-2028
Figure 10-1: Global – Breast Cancer Incidences (Million), 2020 & 2040
Figure 10-2: Global – Breast Cancer Mortality (Million), 2020 & 2040
Figure 10-3: Global – Estimated Breast Cancer Cases, 2021-2028
Figure 10-4: US – Estimated Breast Cancer Cases, 2021-2028
Figure 10-5: Europe – Estimated Breast Cancer Cases, 2021-2028
Figure 10-6: China – Estimated Breast Cancer Cases, 2021-2028
Figure 10-7: Japan – Estimated Breast Cancer Cases, 2021-2028
Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 11-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
Figure 11-3: Global – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-4: US – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-5: Europe – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-6: China – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-7: Japan – Estimated Colorectal Cancer Cases, 2021-2028
Figure 12-1: Global – Pancreatic Cancer Incidences, 2020 & 2040
Figure 12-2: Global – Pancreatic Cancer Mortality, 2020 & 2040
Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 12-4: Global – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-5: US – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-6: Europe – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-7: China – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-8: Japan – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 14-1: Global - Cell Therapy Market (US$ Billion), 2020 - 2028
Figure 14-2: Global – Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-3: Global – Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-4: Global – Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-5: Global – Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-6: Global – Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-7: Global – Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-8: Global – Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-9: Global – Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-10: Global – Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-11: Global – Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 15-1: Global – Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
Figure 15-2: Gamma Delta T Cells Favorable Market Parameters
Figure 15-3: Stages of Drug Development
Figure 1-1: History of T cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 2-1: Limitation of CAR T Cell Therapy
Figure 2-2: Limitations of TIL
Figure 2-3: Limitations of Monoclonal Antibodies
Figure 2-4: Drawback of Chemotherapeutic Drugs
Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 4-1: Gamma Delta T Cell Bispecific Antibodies – Mechanism of Action
Figure 4-2: Functional Advantages of ?? T Cells for CAR T Cancer Therapy
Figure 4-3: CAR ?? T Cells – Mechanism of Action
Figure 5-1: ADI-001 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-2: LAVA-051 – Initiation & Completion Year of Phase-I/II Clinical Trial
Figure 5-3: DRI Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-4: Adoptive Cell Therapy – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-5: GDX012 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 5-6: GDT002 – Initiation & Completion Year of Phase-I Clinical Trial
Figure 6-1: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Company, 2022 till 2028
Figure 6-2: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Country, 2022 till 2028
Figure 6-3: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Indication, 2022 till 2028
Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase, 2022 till 2028
Figure 8-1: Global – Leukemia Incidences & Mortality (Million), 2020 & 2040
Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
Figure 8-3: Mechanism of Action of V?9/CD123 Bispecific Antibody
Figure 8-4: Global – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-5: US – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-6: Europe – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-7: China – Estimated Leukemia Cancer Cases, 2021-2028
Figure 8-8: Japan – Estimated Leukemia Cancer Cases, 2021-2028
Figure 9-1: Global – Lung Cancer Incidences & Mortality (Million), 2020 & 2040
Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer
Figure 9-3: Global – Estimated Lung Cancer Cases, 2021-2028
Figure 9-4: US – Estimated Lung Cancer Cases, 2021-2028
Figure 9-5: Europe – Estimated Lung Cancer Cases, 2021-2028
Figure 9-6: China – Estimated Lung Cancer Cases, 2021-2028
Figure 9-7: Japan – Estimated Lung Cancer Cases, 2021-2028
Figure 10-1: Global – Breast Cancer Incidences (Million), 2020 & 2040
Figure 10-2: Global – Breast Cancer Mortality (Million), 2020 & 2040
Figure 10-3: Global – Estimated Breast Cancer Cases, 2021-2028
Figure 10-4: US – Estimated Breast Cancer Cases, 2021-2028
Figure 10-5: Europe – Estimated Breast Cancer Cases, 2021-2028
Figure 10-6: China – Estimated Breast Cancer Cases, 2021-2028
Figure 10-7: Japan – Estimated Breast Cancer Cases, 2021-2028
Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 11-2: Mechanism Underlying B7-H3 Regulating ?? T Cells Killing Colon Cancer Cells
Figure 11-3: Global – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-4: US – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-5: Europe – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-6: China – Estimated Colorectal Cancer Cases, 2021-2028
Figure 11-7: Japan – Estimated Colorectal Cancer Cases, 2021-2028
Figure 12-1: Global – Pancreatic Cancer Incidences, 2020 & 2040
Figure 12-2: Global – Pancreatic Cancer Mortality, 2020 & 2040
Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 12-4: Global – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-5: US – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-6: Europe – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-7: China – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 12-8: Japan – Estimated Pancreatic Cancer Cases, 2021-2028
Figure 14-1: Global - Cell Therapy Market (US$ Billion), 2020 - 2028
Figure 14-2: Global – Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-3: Global – Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-4: Global – Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-5: Global – Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-6: Global – Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-7: Global – Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-8: Global – Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-9: Global – Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-10: Global – Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 14-11: Global – Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2022-2028
Figure 15-1: Global – Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
Figure 15-2: Gamma Delta T Cells Favorable Market Parameters
Figure 15-3: Stages of Drug Development
LIST OF TABLES
Table 8-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 9-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 10-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 11-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 12-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 8-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 8-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2022-2028
Table 9-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 9-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2022-2028
Table 10-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 10-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2022-2028
Table 11-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 11-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2022-2028
Table 12-1: Global – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-2: US – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-3: Europe – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-4: China – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
Table 12-5: Japan – Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2022-2028
